LENZ Therapeutics, Inc.LENZNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank50
3Y CAGR+5.1%
5Y CAGR+21.9%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+5.1%/yr
Annual compound
5Y CAGR
+21.9%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
2.7x
Strong expansion
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$24.54M-17.7%
2024$29.80M-49.9%
2023$59.50M+181.7%
2022$21.13M-44.3%
2021$37.93M+315.8%
2020$9.12M-
2019$0.00-